The MR Egger method demonstrated that PCSK9 inhibitor has the potential to decrease the risk in patients with menorrhagia (OR [95%CI] = 0.8798 [0.7593, 1.0004], p=4.82× 10−2) (refer to Figure 3). The gene discussed is PCSK9; the disease is Menorrhagia.